Mark Yarchoan, Associate Professor at Johns Hopkins Hospital and Co-Founder and CSO at Adventris Pharmaceuticals, shared on X:
“11% of patients treated with histotripsy die within 30 days.
Is this ‘noninvasive’ procedure more dangerous than advertised or is absurd Facebook marketing driving its use in patients who shouldn’t receive?
Either way, data will catch up with the hype”
Title: Early Outcomes of Histotripsy for Liver Tumors in US Clinical Practice
Authors: Olivia Sears, Elio R. Bitar, Kaelyn C. Cummins, Natalie Blatz, Maclean Cook, Daniel Sheeran, Allan Tsung
Other articles featuring Mark Yarchoan on OncoDaily.